Choosing the number of doses and the cohort size for phase 1 dose-escalation studies

Drug Information Journal

Volumn 39, Issue 2, 2005, Pages 125-137

  Zhou, Yinghui ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Bayesian statistics; Computer software; Decision procedure; Dose escalation; Phase 1 study

Indexed keywords

BAYES THEOREM; COHORT ANALYSIS; COMPUTER PROGRAM; DECISION MAKING; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; MATHEMATICAL ANALYSIS; METHODOLOGY; ONCOLOGY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIMULATION; SINGLE DRUG DOSE;

EID: 18444388031     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150503900203     Document Type: Review

References (16)

1. O'Quigley J, Pepe M, Fisher L. Continual Reassessment Method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46:33-48.
2. Carter SK. Study design principles in the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In: Staquet MJ, ed. The Design of Clinical Trials in Cancer Therapy. Brussels, Belgium: Editions Scientific Europe; 1973;242-289.
3. Møller. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med. 1995;14:911-922.
4. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. A comparison of two phase I designs. Stat Med. 1994;13:1799-1806.
5. O'Quigley J, Reiner E. A stopping rule for the continual reassessment method. Biometrika. 1998;85:741-748.
6. Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med. 2001;20:2827-2843.
7. Whitehead J, Brunier H. Bayesian decision procedures for dose determining experiments. Stat Med. 1995;14:885-893.
8. Whitehead J, Williamson D. An evaluation of Bayesian decision procedures for dose-finding studies. J Biopharma Stat. 1998;8:445-467.
9. Zhou Y, Whitehead J. Practical implementation of Bayesian dose-escalation procedures. Drug Inf J. 2003;37:45-59.
10. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ. Phase I clinical trial of the flavonoid quercetin - pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996;2:659-668.
11. Zhou Y, Whitehead J. Bayesian ADEPT: Operating Manual. Reading, United Kingdom: The University of Reading; 2002.
12. Patterson S, Francis S, Ireson M, Webber D, Whitehead J. A novel Bayesian decision procedure for early-phase dose finding studies. J Biopharma Stat. 1999;9:583-597
13. Whitehead J, Zhou Y, Patterson S, Webber D, Francis S. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics. 2001;2:47-61.
14. O'Quigley J, Hughes M, Fenton T. Dose-finding designs for HIV studies. Biometrics. 2001;57:1018-1029.
15. Braun TM. The Bivariate CRM: Extending the CRM to phase I trials of two competing outcomes. Control Clin Trials. 2002;23:240-255.
16. Whitehead J, Zhou Y, Stevens J, Blakey G, Price J, Leadbetter J. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Stat Med. 2005;24. In press.